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ABSTRACT 
One of the major breakthroughs on adoptive cell transfer (ACT) is autologous T cells transfer that either derived from tumour infiltrating lymphocytes 
(TILs) or genetically engineered T cells, which express tumour recognizing receptors. Between those two, when the purpose is to treat solid tumours, a 
more impressive clinical trial result is demonstrated by TIL therapy. The efficacy of TIL therapy is due to its highly personalized approach in generating 
T cells from the patient’s own tumour tissue. Regardless to its efficacy, TIL therapy in a commercial setting is limited, mainly due to the complexity and 
costs of cell expansion protocols. This issue has triggered the need to develop effective methods to expand TILs ex vivo, in a safe, efficient, and 
reproducible manner. In line with this need, there are two main types of bioreactors that have recently been used to generate T cells for ACT, which 
might suit the requirements for TIL manufacture. Therefore, in this review, we highlighted recent updates on TILs expansion protocol, particularly in 
autologous settings, as well as the aspect of each bioreactor to be considered before integrating them into TIL manufacturing process.  
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INTRODUCTION 
Adoptive cell transfer (ACT) is a treatment that uses immune system 
cells to eliminate cancers. In cancer therapy, an ACT-based strategy 
exploits the killing potency of specific T cells to generate a robust 
immune-mediated anti-tumor response. This anti-tumor response is 
achieved by manipulating T cells ex vivo, away from the patient’s 
immune-suppressive environment, followed by expansion and 
reinfusion back to the patient [1, 2].  
Based on the way that T cells are manipulated, ACT-based strategy 
can be divided into two platforms, i.e. isolation of naturally 
occurring tumor-specific T cells from existing tumour masses, which 
is called tumour infiltrating lymphocytes (TILs) platform [1, 2], and 
genetic modification of blood-derived T cells to allow specific 
recognition of tumour cells, which is called chimeric antigen 
receptor (CAR) T-cell or T-cell receptor (TCR) platform [1-4]. Both 
platforms have demonstrated impressive, durable response in 
clinical settings to treat certain tumours, so that FDA approved CAR 
T-cell therapy for treating hematological malignancies and TIL 
therapy for treating melanoma and persistent cervical cancer [1, 2].  
Despite various successes in treating B-cell leukaemia and 
lymphomas, CAR T-cell therapies have not demonstrated their 
efficacy in solid tumours. As hematological malignancies make up 
only a small fraction of all cancers, TIL platform is most likely to 
have broader applicability for treating solid tumours [2, 5, 6]. 
However, in autologous cell therapy, current TIL expansion 
protocols remain facing challenges that are mainly due to limited T 
cell number, which can be isolated from a patient tumour. Moreover, 
although a TIL’ rapid expansion protocol has been developed 
decades ago by Rosenberg in 1988 [7], the protocol still needs to be 
simplified to allow efficient scale-up for TIL manufacturing. For this 
review, we searched various databases, i.e. Pubmed, Science Direct, 
Springer, and Innovare Academic Sciences, using keywords: “tumour 
infiltrating lymphocyte” and “Bioreactor” at 30 December 2019, 
without time limits. Only English literatures were used. 
The main aim of this review is to present a brief outline of the basic 
concepts of TILs in treating solid tumours, as well as general 
protocols for ex vivo TIL expansion that are currently being used in 
clinical application. In addition, three bioreactors that have been 
used in many commercial ACT services, i.e. GE Wave, G-Rex, and 
Quantum are also discussed here along with general considerations 
of integrating them into TIL ex vivo expansion protocol.  
TIL basic concept in treating solid tumours 
TILs are a heterogeneous population of lymphocytes, which 
primarily consist of T and natural killer (NK) cells that naturally 
migrate into tumours and are potentially present in any solid 
tumour [1, 7, 8]. Among these two subsets, a more effective killing 
capability is owned by T-cells because they can recognize tumour 
associated antigens (TAAs) due to the presence of endogenous T cell 
receptors (TCRs). Therefore, exploiting TIL’ killing capacity was 
studied extensively to target solid tumour, which further led to FDA 
approval for treating cervical cancer and metastatic melanoma [2, 5].  
Compared to CAR T-cell platform in terms of treating solid tumours, 
TILs have several advantages. Despite both CAR T-cells and TILs have 
the ability to recognize TAAs, TILs have a wider coverage of TAAs. TILs 
that are extracted from tumour resection consist of clones that are 
able to recognize multiple TAAs, while CAR T-cells, which require an 
artificial engineered antigen receptor, can only recognize a single TAA. 
Moreover, since TILs are naturally formed to target tumour neo-
antigens, this platform offers minimum adverse effects that are caused 
by unpredicted off-target effects on other tissues. Table 1 describes the 
competitive advantages of TIL therapy on treating solid tumours in 
comparison with CAR T-cell platform [9]. 
Currently, TILs are implemented as autologous-based cell therapy, 
but generating highly activated T cells in sufficient numbers from 
tumours requires a protocol that is able to overcome the limited 
number of TILs, which are extracted from patient tumour tissue. 
Therefore, an effective and efficient expansion protocol is highly 
needed. 
General protocols for TIL ex vivo expansion 
Ex vivo expansion of TILs requires several steps to get a sufficient 
number of activated T cells. A preliminary report by Rosenberg et al. 
in 1988 paved the way for the development of a standard method for 
large-scale in vitro expansion of TILs that were isolated from a 
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patient’s tumour [7]. As depicted in fig. 1, the method involves three 
main steps. It starts with TIL extraction from a patient’s tumour 
tissue, rapid expansion protocol (REP), which consists of TIL 
expansion using high dose IL-2 and co-culture with feeder cells to 
generate enough cells for ACT, and finally harvest and preparation of 
TILs before reinfusion back to the patient [7, 8, 10, 11]. The 
following sections described those three steps that are involved in 
TIL ex vivo expansion. 
 
Table 1: The competitive advantages of TIL therapy on treating solid tumors compared to CAR T-cell platform 
References Comparison  TILs CAR T cells 
[9] Technology platform No genetic modification Genetic modification 
[9] T cells’ source Tumour tissue Peripheral blood 
[9] Usage  Autologous, no HLA restriction Autologous, no HLA restriction 
[9] Target coverage Multiple tumour antigens Single surface tumour antigen 
[9] Risk of adverse effect Minimal chance of off-target effect on other 
tissues 
Potential off-target effect on other tissues 
(immunogenic), cytokine release syndrome 
[9] Type of treatment One time treatment One time treatment 
[9] Utility  
 
Solid tumours: evidence in melanoma and 
cervical cancers 




Fig. 1: TIL ex vivo expansion workflow [7, 8, 10, 11] 
 
There are three main steps in ex vivo TIl expansion: 1. Extraction of 
TILs from a patient own tumour, 2. Rapid expansion protocol using 
high dose of IL-2 followed by activation by OKT3 expressing feeder 
cells, and expansion to billion numbers of TILs ex vivo, 3. Harvesting 
and preparation of ready to use expanded TILs in infusion bag to be 
re-infused back to a lymphocyte-depleted patient [7, 8, 10, 11] 
TIL extraction 
In general, based on a previously described method by Dudley et al. in 
2003 [8], there are three feasible methods for initiating TIL culture 
that started from the patient’s dissected tumours. The first method is 
to grow TILs from multiple tumour fragments individually as explant 
cultures in IL-2 prior to culture expansion. The second method is by 
enzymatic digestion, and the third one is by using mechanical 
intervention to yield single cells and/or small aggregates from the 
tumour. The three methods were started from biopsy specimens that 
are free from normal and necrotic tissues. Biopsy specimens were then 
cut into 1 to 2 mm dimension using a sharp scalpel [8].  
In the first method, each tumour fragments are placed in single wells 
of 24-well tissue culture plates with 2 ml of complete medium (CM) 
and cultured. The CM contains 25 mmol/l HEPES pH 7.2, penicillin 
and streptomycin (100 U and 100μg/ml), 2 mmol/l L-glutamine, 5.5 
x 10-5
In the second method, which uses enzymatic digestion, the tumour 
fragments are immersed in a medium that contains collagenase, 
hyaluronidase and DNAse in RPMI 1640 overnight with gentle agitation 
to cause enzymatic degradation. Following filtration to remove 
undigested tissue chunks, the single cells are washed in Hanks Balanced 
Salt Solution (HBSS) prior to purification using single-step Ficoll gradient 
centrifugation. The purified cells are re-suspended in similar CM as the 
first method and dispensed in wells of 24-well plates at 1 x 10
 mol/l β-mercaptoethanol, 10% human serum and 6000 IU/ml 
IL-2 in RPMI 1640. The culture is incubated in a humidified 
incubator at 37 °C with 5% CO2, and daily inverted-microscope 
inspection is done to observe lymphocyte proliferation. This method 
takes about 1 to 2 w to yield a monolayer of lymphocytes prior to 
further expansion [8]. 
6 
The last technique for TIL culture initiation is to use mechanical 
intervention such as homogenizer to disrupt cell aggregates. In the 
case of melanoma-derived TILs, physical disaggregation can be 
done using a disposable sterile mini homogenizer i.e. 50 μm 
Medicon© chamber (Beckton Dickinson). In brief, several 
fragments, which are about 2 mm dimension each, are forced 
across a small grater inside the Medicon© chamber. The resulting 
cells and aggregates are then washed and re-suspended in CM 
without IL-2, followed by Ficoll gradient centrifugation. After 20 
min’ centrifugation at 2000 rpm, TIL containing lower interface is 
taken and washed. TILs are then plated in 24-well plates and 
cultured exactly as the first method [8].  
cells/ml. 
The cultures are further incubated in a humidified incubator at 37 °C 
with 5% CO2, and the monitoring step is done as the first method [8].  
Rapid expansion protocol  
The term “rapid expansion protocol” (REP) was introduced by 
Rosenberg et al. [7]. It refers to a protocol for TIL expansion that is 
derived from lymphocytes after TIL extraction step. In this method, 
unselected lymphocytes are exposed to IL-2, which usually causes 
expansion to 40-50 millions of total cells within 2-4 w [12]. The 
resulting bulk of lymphocytes are called “young TILs”, which then 
undergo either CD8+
Subsequent activation step of either CD8
enrichment step using magnetic-beads 
separation [13], or are directly subjected to activation step [12].  
+-enriched or 
heterogeneous young TILs requires OKT3 (anti-CD3) antibody and 
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high dose IL-2 in the presence of irradiated allogeneic feeder cell 
layer to induce TIL proliferation. Feeder cells are usually peripheral 
blood mononuclear cells (PBMCs) that are taken from healthy 
subjects with HLA mismatch, which help “young TILs” to further 
proliferate and be activated. Prior to co-culture step, PBMCs undergo 
irradiation (50 Gy) to inhibit their proliferation and induce 
apoptosis. In brief, PBMC (2x108) and “young TILs” (1x106) are co-
cultured in the presence of anti-OKT3 antibody in a medium that 
contains CM without IL-2 and AIM V medium at a ratio of 1:1. The 
cultures are grown in flasks and incubated at 37 °C with 5% CO2
Harvest and preparation for infusion 
. On 
day-2, IL-2 (6000 IU/ml) is added. Medium change is carried out by 
removing 50% of culture supernatant and replacing it with the same 
fresh 6000 IU/ml IL-2 containing medium. On day 6 and every day 
thereafter, cell concentration is determined and undergoes either 
continuing culture in additional flasks or being harvested for 
infusion purpose [8]. 
Prior to reinfusion, TILs should be prepared in an appropriate saline 
medium. The medium during REP is removed by centrifugation, and the 
cell pellets are washed in 0.9% sodium chloride. After another 
centrifugation step, TILs are then re-suspended in 0.9% sodium chloride 
with 2.5% human albumin and ready for intravenous administration [8]. 
TIL manufacturing for solid tumour therapy 
Manufacturing TILs for cancer therapy requires a tight operational 
network for efficient clinical implementation. While tissue extraction 
and patient preparation toward the reinfusion process can be 
carried out in a clinic or hospital setting, TIL-manufacturing requires 
standard current good manufacturing practice (cGMP) process to 
meet a clinical-grade cellular product that contains highly activated 
T-cells before continuing to reinfusion step (fig. 2). An optimum 
culture system with efficient labour hour and manufacture cost is a 
priority in TIL manufacturing [7, 8, 10, 11]. 
 
 
Fig. 2: A schematic diagram of TIL manufacturing for autologous therapy [7, 8, 10, 11] 
 
In general, the setting can be divided into three consecutive 
processes i.e.: (i) extraction of TILs from patient tumour tissue, (ii) 
T-cell manufacture that involves TIL extraction, rapid expansion and 
harvesting, and (iii) delivering TILs to lymphocyte-depleted patient. 
All processes should be carried out under a predetermined schedule 
according to manufacture capability [7, 8, 10, 11]. 
Bioreactors 
Static tissue culture system was initially used in small-scale clinical 
trials on the basis of batch feeding. However, for larger-scale 
implementation, a static system is labour intensive, complicated and 
expensive. Therefore, simplifying the protocols is a must to meet 
cGMP compliant TILs production criteria. The major drawback of 
this static system is the need of manual intervention during 
culturing, which increases the production cost [14]. There are 
basically two types of bioreactors, which are designed to overcome 
this limitation, i.e. perfusion-based and gas-permeable bioreactors. 
These bioreactors have been described to simplify and streamline 
the production of autologous TIL therapy and can be integrated to 
REP workflow at the step of ‘young TIL’ ex vivo expansion [14-16]. 
In addition to the aforementioned bioreactors, a hollow fibre 
bioreactor is commonly used for T cell cultivation for cell therapy 
purposes. Commercially known as Quantum© Cell Expansion 
System, the hollow fibre bioreactor is basically a modification of 
perfusion-based bioreactor. Instead of using a bag as cell container, 
the system uses hollow–fibres with intra capillary surfaces to 
facilitate cell attachment. The yield of CD3+
Perfusion-based bioreactors 
T cells that were 
generated from this system was very promising [17]. Moreover, a 
hollow-fiber bioreactor has been implemented for TIL expansion 
with good results [18].  
Perfusion-based bioreactor was developed to overcome the 
limitation of static culture system that is solely dependent on 
manual intervention in the distribution of nutrients and oxygen, as 
well as the removal of waste products [19]. The system retains cells 
inside the bioreactor, while it is continually removing cell waste 
products and adding fresh media at the same rate. There are several 
ways to retain cells, such as by using capillary fibres (as developed 
by Quantum©) [17, 18] or membranes to which the cells are 
attached to or another way that is based on a filtration system to 
keep the cells inside a chamber, and periodically exchange the media 
[15, 19]. All types can be integrated with an automatic sensor that 
reports the culture microenvironment.  
One common perfusion-based bioreactor that has been used for TILs 
expansion is GE WAVE bioreactor system (fig. 3). The system uses a 
pre-sterilized inflated cultivation chamber that is called a Cellbag 
during cultivation. It combines a rocking motion to generate a 
“wave” with a system that homogenously distributes oxygen and 
nutrients throughout the Cellbag, and a heater to provide the 
optimum temperature. Sensory patches are attached at the bottom 
of the Cellbag to measure the level of dissolved oxygen and medium 
pH [15, 20-22]. 
 
 
Fig. 3: A schematic diagram of a typical perfusion-based 
bioreactor [15, 20-22]] 
 
This scalable system consists of a cell bag bioreactor, pumps to 
perfuse fresh medium while discharging waste at the same time, a 
range of optional controllers, including sensory patches to monitor 
pH and temperature, and a rocking base [15, 20-22].  
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In the setting of autologous TIL expansion, a bulk of ‘young TILs’ can 
be transferred into Cellbag Bioreactors and placed on a rocking base. 
The Cellbag is further rocked gently for rapid gas transfer and mixing. 
The perfusion functionality of the GE-WAVE allows automatic feeding 
and waste removal, thus reducing the labour intensive aspect for 
controlling cell microenvironment [15, 20-22]. Using this system, cells 
can be rapidly expanded to more than 107
Membrane bioreactors 
cells/ml with a maximum 
capacity of up to 25L cell culture in a single bioreactor [15].  
Basically, membrane bioreactor is a bioreactor that integrates a 
permeable-selective or semi-permeable membrane to allow growth 
of cells in suspension culture by providing active organic and/or gas 
exchange [16]. A typical membrane bioreactor, which was developed 
by Wilson Wolf Manufacturing, is named G-Rex flasks. It was 
designed to fulfil the requirement of highly expanded cells using 
larger medium volumes, particularly for TIL therapy platform. It 
consists of a common culture flask that is equipped with a silicone 
membrane, which is placed at the base of the flask; thus allowing 
efficient O2 and Co2
 
 exchange (fig. 4) [14, 16]. Unlike a perfusion 
bioreactor that requires mechanical assistance to provide a rocking 
motion, a gas-permeable bioreactor is able to support a cell culture 
with a large media volume in a static environment without the need 
of a mechanical agitation. Once the optimal seeding density has been 
reached, the nutrients are not a limiting factor, and cells will remain 
viable during longer period of culture [14, 16].  
 
Fig.4: A cross-sectional view of a gas-permeable flask 
(membrane bioreactor) [16] 
 
The flask has a gas-permeable silicone membrane at the bottom for 
efficient gas exchange, and should be placed inside a conventional 
incubator [16]. 
Using K562 cells, Bajgain et al. [16] showed that the lowest possible 
initial seeding density was 1.25 x 105 cells/cm2, and 10 ml/cm2
Considerations in integrating bioreactor system into TIL 
manufacture 
 of 
medium volume was enough to give a maximum cell number within 
9-10 d. Therefore, implementation of G-Rex flasks into REP workflow 
might result in higher cell number, which was started from a 
minimum number of seeded cells, and a shorter culture period. 
All bioreactors described above offer substantial improvements over 
prior static system [16-22]. Several considerations should be taken 
into account regarding the scaling up of TIL manufacture. On the 
aspect of capital investment, the G-rex system [14, 16] offers a faster 
initiation for scaling up purposes, since it does not need additional 
specialized equipment. It offers a simple scaling up of flasks, which 
can be replaced by G-rex flasks [14, 16], according to patient’s 
requirements that make the translation process from research 
laboratories to cGMP production and validation to become more 
convenient. However, the G-Rex system is not a completely closed 
system [14, 16]. Integrating G-Rex flasks into REP process might be 
slightly complicated than the perfusion system (GE-WAVE or 
Quantum system) at the phase of cell harvesting and seeding [14].  
On the other hand, the perfusion system offers a more convenient 
way on handling cultures in larger volumes, as the system facilitates 
medium exchange automatically without additional bioreactor bags 
for larger culture quantities [15, 20-22]. In comparison with the G-
Rex system, which requires almost thirty G-Rex Flasks per patient 
treatment [14], the package of perfusion system, which can support 
up to 25 L culture in a single bioreactor [15], is more convenient.  
GE-WAVE and G-Rex bioreactors were used in scaling up of TILs [14-
16, 20-22] and demonstrated impressive clinical results following 
TILs therapy for melanoma and cervical cancer [12-14], which 
further reinforce the commercial potential of TIL therapy. Further, 
the Quantum system [17, 18], which was used to culture TILs and 
scale-up CD3+
CONCLUSION 
T-cells, might also be a candidate for scaling up of TILs. 
Adoptive TIL therapy holds potential for treating solid tumours in 
term of reducing adverse effects to host. Issues regarding limitation 
in cell number could be overcome by determining an optimum 
combination between cell source, culture initiation and bioreactor 
system. The WAVE and G-Rex bioreactors were successfully used in 
scaling up TILs in clinical settings. Both systems come with benefits 
and drawbacks to be considered. With an increasing number of 
commercially available advanced bioreactors including the Quantum 
system, facilitation of mass production of TILs in a short term 
culture period will become real soon.  
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